Equipalazone

1 x 50 ml

Solution for injection

Active substance

Phenylbutazone : 200 mg/ml

ATC code

QM01AA01 Phenylbutazone

QM01AA Butylpyrazolidines

QM01A Antiinflammatory and antirheumatic products, non-steroids (NSAIDs)

QM01 Antiinflammatory and antirheumatic products

QM Musculo-skeletal system

Species

Horses and ponies (non-food producing).

Indications

For the treatment of musculoskeletal disorders in horses and ponies where the antiinflammatory and analgesic properties of phenylbutazone can offer relief against inflammation, pain and lameness (for example, osteoarthritis, acute and chronic laminitis, bursitis and carpitis).

Dose to be administered and administration route

Intravenous use.

Horses 450 kg (1000 lb) bodyweight: Maximum 10 ml (4.4 mg phenylbutazone/kg).

Ponies 225 kg (500 lb) bodyweight: Maximum 5 ml (4.4 mg phenylbutazone/kg).

To be administered by very slow intravenous injection in a single dose, which may be followed if necessary by oral phenylbutazone therapy commencing 24 hours after the injection.

In acute cases and in hospitalised animals it may be administered once daily for not more than five consecutive days.

Observe aseptic conditions.

Adverse reactions

Horses and ponies (non-food producing):

Rare

(1 to 10 animals / 10,000 animals treated):

Collapse^a

Very rare

(<1 animal / 10,000 animals treated, including isolated reports):

Injection site reaction^b

^a following intravenous injection. The product should be injected slowly over as long a period as is reasonably practical. At the first signs of intolerance, the administration of the injection should be interrupted.

^b if the injection is accidentally inoculated under the skin during intravenous administration.

Non-steroidal anti-inflammatory drugs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.